Skip to main content


Fig. 1 | BMC Cancer

Fig. 1

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Fig. 1

Kaplan-Meier estimates for OS in the axitinib- and placebo-titration arms. Modified from Rini et al. [3], Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma, p 500, copyright 2016, with permission from Elsevier. Abbreviations: CI confidence interval, LLN lower limit of normal, mOS median overall survival, NE not estimable, OS overall survival

Back to article page